证券代码：000597 证券简称：东北制药 公告编号：2025-053 东北制药集团股份有限公司 关于公司董事会秘书辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特此公告。 东北制药集团股份有限公司董事会 传真：024-25806400 电子邮箱：dshbgs@nepharm.com.cn 联系地址：沈阳经济技术开发区昆明湖街8号 东北制药集团股份有限公司（以下简称"公司"）董事会于近日收到公司董事 会秘书阎小佳先生的书面辞职报告。由于个人原因，阎小佳先生申请辞去公司董事 会秘书职务，其辞职后将不在公司及公司下属企业任职。根据《深圳证券交易所股 票上市规则》等有关规定，该辞职报告自送达董事会时生效。 截至本公告披露日，阎小佳先生未持有公司股份，不存在应当履行而未履行或 仍在履行中的承诺事项。阎小佳先生在担任公司董事会秘书期间，勤勉尽责，恪尽 职守，公司及董事会对阎小佳先生在任职期间所做出的贡献表示衷心感谢！ 根据《深圳证券交易所股票上市规则》等相关规定，公司将尽快聘任董事会秘 书，新任董事会秘书履职前，暂由公司董事长周凯先生代行董事会秘书职责。 ...

Core Viewpoint - Northeast Pharmaceutical (000597) announced the resignation of its board secretary Yan Xiaojia due to personal reasons, effective upon delivery of the resignation letter to the board [1] Group 1 - Yan Xiaojia did not hold any shares in the company [1] - The company will promptly appoint a new board secretary [1] - During the interim period, the chairman Zhou Kai will act in the role of board secretary [1]

Core Insights - Northeast Pharmaceutical has successfully transformed over the past seven years, breaking through institutional barriers and embracing market opportunities under the mixed-ownership reform led by Liaoning Fangda Group [1] Group 1: Product and Market Positioning - The company maintains a strong commitment to affordable healthcare, exemplified by its production of low-cost medications such as paracetamol tablets priced at 2 yuan per pack and vitamin C tablets at 1.60 yuan per bottle, ensuring consistent supply [2] - Northeast Pharmaceutical has passed a rigorous FDA inspection with zero defects, demonstrating its commitment to high-quality standards and gaining access to international markets [2] - The company has invested nearly 300 million yuan in social initiatives, including poverty alleviation and disaster relief, reinforcing its dedication to public welfare [2] Group 2: Management and Operational Efficiency - Northeast Pharmaceutical has implemented a system that encourages employee suggestions, resulting in the collection of 1,345 proposals in the past year, with over 900 being adopted, enhancing operational efficiency [3] - The company has streamlined its decision-making processes, allowing for quicker resolutions of production and sales issues, reflecting the effective management practices adopted from Fangda Group [3] Group 3: Innovation and R&D - Following its mixed-ownership reform, Northeast Pharmaceutical has significantly increased its R&D investments and established a biological research base in Shanghai, focusing on high-potential new drug projects [4] - The acquisition of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. has strengthened the company's capabilities in cell therapy, leading to the development of over ten immune therapy products targeting various cancers [4] - This strategic positioning has enabled Northeast Pharmaceutical to enter the leading tier of the cell therapy market, opening new avenues for biopharmaceutical innovation [4]

Core Insights - The article highlights the transformation of Northeast Pharmaceutical over the past seven years, emphasizing its partnership with the Liaoning Fangda Group, which has led to significant reforms and resource restructuring, resulting in a revitalized company focused on high-quality development [1] Quality Commitment - Northeast Pharmaceutical has maintained a strong commitment to quality, exemplified by its successful passing of an international audit for dietary supplements, achieving a "zero defect" status [2] - The company has invested nearly 300 million yuan in social contributions over the past seven years, focusing on industry poverty alleviation and rural revitalization [2] System Activation - The company has established a robust suggestion system that encourages employees to propose improvements, resulting in over 1,300 suggestions received in the past year, with more than 900 implemented [3] - An effective incentive mechanism has been created, rewarding employees with over 27 million yuan for various innovations in the past three years [3] Risk Management and Innovation - Following its integration into Fangda Group, Northeast Pharmaceutical has adopted advanced management practices, establishing a comprehensive risk control mechanism for major contracts [4] - The company has significantly increased its R&D investment, focusing on identifying high-potential new drug projects through a multi-faceted approach, including independent and collaborative development [4][5] - Northeast Pharmaceutical has developed a robust R&D system in cutting-edge technologies such as TCR-T and CAR-T, positioning itself among the leaders in cell therapy and opening new avenues in biopharmaceutical innovation [5]

Core Viewpoint - The transformation of Northeast Pharmaceutical over the past seven years highlights its shift from traditional manufacturing to a focus on biopharmaceutical innovation, driven by mixed-ownership reform and a commitment to social responsibility [1][5]. Group 1: Company Transformation - Since joining the Liaoning Fangda Group in 2018, Northeast Pharmaceutical has broken free from institutional constraints and embraced innovation, leading to high-quality development [1]. - The company has successfully transitioned from a rigid structure to a vibrant, market-responsive organization, emphasizing biopharmaceutical advancements [1][5]. Group 2: Commitment to Public Welfare - Northeast Pharmaceutical offers affordable medications, such as acetaminophen tablets priced at 2.00 yuan per pack, reflecting its dedication to public health and accessibility [2]. - The company has invested nearly 300 million yuan in social welfare initiatives over the past seven years, demonstrating its commitment to corporate social responsibility [2]. Group 3: Employee Engagement and Innovation - The company has established effective channels for employee suggestions, resulting in the acceptance of over 900 out of 1,345 proposals in the past year, fostering a culture of innovation [4]. - A reward mechanism has been implemented, with over 27 million yuan allocated for innovation incentives in the last three years, enhancing employee motivation and creativity [4]. Group 4: Focus on Biopharmaceutical Innovation - Northeast Pharmaceutical has increased its R&D investment and adopted a three-pronged approach of independent research, joint development, and project acquisition to establish a foothold in the biopharmaceutical sector [5]. - The establishment of a biological research base in Shanghai and the acquisition of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. have positioned the company in the cell therapy market, developing over ten targeted cell therapy products for various cancers [5]. - The company is actively recruiting PhD and master's level talent to strengthen its research capabilities, aiming to become a leader in the biopharmaceutical field [5].

Core Viewpoint - Northeast Pharmaceutical has successfully transformed from traditional manufacturing to innovation-driven development since its mixed-ownership reform in 2018, significantly increasing its R&D investment and establishing itself in the advanced cell therapy sector [1][2]. Group 1: Innovation Strategy and Development - Before the mixed-ownership reform, Northeast Pharmaceutical struggled with slow market responses and insufficient R&D investment. Post-reform, the company has leveraged new advantages to enhance R&D efforts and accurately identify high-potential new drug projects [2]. - The company has adopted a three-pronged approach of "independent R&D + joint development + project introduction," establishing a biological R&D base in Shanghai and acquiring Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., which has a unique technology platform in solid tumor cell therapy [2]. - In the first half of this year, Northeast Pharmaceutical initiated large-scale recruitment of master's and doctoral talents to strengthen its research capabilities, aiming to create a talent hub and technical benchmark in the biopharmaceutical field [2]. Group 2: Technological Achievements - Under the guidance of its innovation strategy, Northeast Pharmaceutical has achieved significant technological results, with 22 new products approved for production in the past four years, including various injection solutions and tablets that have contributed to continuous growth in operating performance [3]. - The company has developed over 10 tumor-targeted cell therapy products for diseases such as pancreatic cancer and colorectal cancer, enhancing its market competitiveness and providing new treatment hopes for patients [3]. - Northeast Pharmaceutical is advancing the construction of intelligent production lines, achieving full-process control and improving production efficiency while ensuring product quality stability and reliability [3]. Group 3: Social Responsibility and Employee Welfare - Northeast Pharmaceutical has invested nearly 300 million yuan in social donations for industrial poverty alleviation, rural revitalization, and pandemic relief, demonstrating its commitment to social responsibility [4]. - The company has established a comprehensive welfare policy system covering healthcare, education, and elderly care, distributing over 1.2 billion yuan in various benefits and cash bonuses to employees since the mixed-ownership reform [4]. - Looking ahead, Northeast Pharmaceutical plans to continue its commitment to social contributions and increase R&D investments in the biopharmaceutical sector to support the "Healthy China" strategy [4].

近日，东北制药集团股份有限公司（以下简称"公司"）子公司沈阳东瑞精细化工有限公司（以下简 称"东瑞公司"）收到辽宁省沈阳市中级人民法院（以下简称"市中院"）民事判决书。上诉人（原审被 告）东瑞公司因与被上诉人（原审原告）谭敏娟、苏锋、徐素珍、杨井强、世恒谦、闫明福、张玲、王 怀信、肖强请求东瑞公司收购股份纠纷一案，不服沈阳经济技术开发区人民法院民事判决，向市中院提 起上诉。该案现已审理终结。 案件起源详见公司于2024年12月11日在巨潮资讯网披露的《东北制药集团股份有限公司关于子公司涉及 诉讼的公告》（公告编号：2024-068）。 二、本次诉讼事项的进展情况 （一）辽宁省沈阳市中级人民法院民事判决书（2024）辽01民终21321号 上诉人（原审被告）：沈阳东瑞精细化工有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本次诉讼事项的基本情况 被上诉人（原审原告）：谭敏娟 二审第三人：东北制药集团股份有限公司 东瑞公司上诉请求：1.请求二审法院撤销（2023）辽0191民初8715号民事判决书，依 ...

二、本次诉讼事项的进展情况 （一）辽宁省沈阳市中级人民法院民事判决书（2024）辽 01 民终 21321 号 上诉人（原审被告）：沈阳东瑞精细化工有限公司 被上诉人（原审原告）：谭敏娟 证券代码：000597 证券简称：东北制药 公告编号：2025-052 东北制药集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次诉讼事项的基本情况 近日，东北制药集团股份有限公司（以下简称"公司"）子公司沈阳东瑞精 细化工有限公司（以下简称"东瑞公司"）收到辽宁省沈阳市中级人民法院（以 下简称"市中院"）民事判决书。上诉人（原审被告）东瑞公司因与被上诉人（原 审原告）谭敏娟、苏锋、徐素珍、杨井强、世恒谦、闫明福、张玲、王怀信、肖 强请求东瑞公司收购股份纠纷一案，不服沈阳经济技术开发区人民法院民事判决， 向市中院提起上诉。该案现已审理终结。 案件起源详见公司于 2024 年 12 月 11 日在巨潮资讯网披露的《东北制药集 团股份有限公司关于子公司涉及诉讼的公告》（公告编号：2024-068）。 二审第三人：东北制药集团股份有限公司 东瑞公司上诉请求： ...

证券代码：000597 证券简称：东北制药 公告编号：2025-052 东北制药集团股份有限公司 关于子公司涉及诉讼的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次诉讼事项的基本情况 近日，东北制药集团股份有限公司（以下简称"公司"）子公司沈阳东瑞精 细化工有限公司（以下简称"东瑞公司"）收到辽宁省沈阳市中级人民法院（以 下简称"市中院"）民事判决书。上诉人（原审被告）东瑞公司因与被上诉人（原 审原告）谭敏娟、苏锋、徐素珍、杨井强、世恒谦、闫明福、张玲、王怀信、肖 强请求东瑞公司收购股份纠纷一案，不服沈阳经济技术开发区人民法院民事判决， 向市中院提起上诉。该案现已审理终结。 案件起源详见公司于 2024 年 12 月 11 日在巨潮资讯网披露的《东北制药集 团股份有限公司关于子公司涉及诉讼的公告》（公告编号：2024-068）。 二、本次诉讼事项的进展情况 （一）辽宁省沈阳市中级人民法院民事判决书（2024）辽 01 民终 21321 号 上诉人（原审被告）：沈阳东瑞精细化工有限公司 被上诉人（原审原告）：谭敏娟 二审第三人：东北制药集团股 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-051 东北制药集团股份有限公司 关于公司副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）于近日收到副总经理冯晓先 生的书面辞职报告，因达到法定退休年龄，冯晓先生申请辞去公司副总经理职务， 其辞职后将不在公司及公司下属企业任职。根据《深圳证券交易所股票上市规则》 等有关规定，该辞职报告自送达董事会时生效，其辞职不会影响公司的正常运行。 截至本公告披露日，冯晓先生未持有公司股份，不存在应当履行而未履行或仍 在履行中的承诺事项。 公司董事会对冯晓先生在任期间的勤勉工作和对公司发展所作出的贡献表示衷 心的感谢！ 特此公告。 东北制药集团股份有限公司董事会 2025年7月3日 ...